EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis

Arun J Sanyal, Philip N Newsome, Iris Kliers, Laura Harms Østergaard, Michelle T Long, Mette Skalshøi Kjær iD, Anna M G Cali, Elisabetta Bugianesi, Mary E Rinella, Michael Roden, Vlad Ratziu, ESSENCE Study Group

New England Journal of Medicine · 05.06.2025 · 392 (21) · 2089-2099

DOI: 10.1056/nejmoa2413258 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 05.06.2025. Verfasst von Arun J Sanyal und 11 weiteren Autor:innen. Beteiligte Einrichtung: Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, Virginia Commonwealth University School of Medicine, Richmond. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Liver Cirrhosis, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 1244-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Novo Nordisk A/S.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsLiver CirrhosisNon-alcoholic Fatty Liver DiseaseAdultAgedFemaleHumansMaleMiddle AgedDouble-Blind MethodInjections, SubcutaneousLiverFollow-Up StudiesTreatment OutcomeSeverity of Illness IndexBiopsyDrug Administration ScheduleGlucagon-Like Peptide 1Semaglutide

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, Virginia Commonwealth University School of Medicine, Richmond.
  • Roger Williams Institute of Liver Studies, Faculty of Life Sciences and Medicine, King's College London, Foundation for Liver Research and King's College Hospital, London.
  • College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
  • Novo Nordisk, Bagsværd, Denmark.
  • Department of Medical Sciences, University of Turin, Turin, Italy.
  • Division of Gastroenterology, Hepatology, and Nutrition, University of Chicago, Chicago.

ORCID-Profile: Mette Skalshøi Kjær

Förderung

  • Novo Nordisk A/S

Zitieren

APA

Sanyal, A. J., Newsome, P. N., Kliers, I., Østergaard, L. H., Long, M. T., Kjær, M. S., Cali, A. M. G., Bugianesi, E., Rinella, M. E., Roden, M., Ratziu, V., & ESSENCE Study Group (2025). Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis. New England Journal of Medicine, 392(21), 2089-2099. https://doi.org/10.1056/nejmoa2413258

Vancouver

Sanyal AJ, Newsome PN, Kliers I, Østergaard LH, Long MT, Kjær MS, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis. New England Journal of Medicine. 2025;392(21):2089-2099. doi:10.1056/nejmoa2413258

BibTeX
@article{Sanyal2025,
  author = {Sanyal, Arun J and Newsome, Philip N and Kliers, Iris and Østergaard, Laura Harms and Long, Michelle T and Kjær, Mette Skalshøi and Cali, Anna M G and Bugianesi, Elisabetta and Rinella, Mary E and Roden, Michael and Ratziu, Vlad and ESSENCE Study Group, ESSENCE Study Group},
  title = {Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {392},
  number = {21},
  pages = {2089--2099},
  doi = {10.1056/nejmoa2413258}
}
Kostenlos starten →